Telix Pharmaceuticals (TLX) Other Non-Current Liabilities (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Other Non-Current Liabilities data on file, last reported at $3.5 million in Q4 2025.

• Other Non-Current Liabilities for Q4 2025 came in at $3.5 million, down 60.95% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.5 million (down 60.95% YoY), and the FY2025 annual result was $3.5 million, changed N/A from the prior year.
• Other Non-Current Liabilities retreated to $3.5 million in Q4 2025 per TLX's latest filing, from $9.0 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $9.0 million in Q4 2024 and troughed at $3.5 million in Q4 2025.
• A 3-year average of $5.9 million and a median of $5.2 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities soared 72.85% in 2024, then tumbled 60.95% in 2025.
• A 3-year view of Other Non-Current Liabilities shows it stood at $5.2 million in 2023, then soared by 72.85% to $9.0 million in 2024, then plunged by 60.95% to $3.5 million in 2025.
• Business Quant data shows TLX's Other Non-Current Liabilities at $3.5 million in Q4 2025, $9.0 million in Q4 2024, and $5.2 million in Q4 2023.